Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy. Sparsentan is an endothelin and angiotensin II receptor antagonist. It was approved for medical use in the United States in February 2023. Medical uses Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy. Society and culture Legal status Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria. References External links Orphan drugs